Journal of Clinical Endocrinology & Metabolism, Vol 81, 542-546, Copyright © 1996 by Endocrine Society

ARTICLES

Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis

P Bettica, AK Taylor, J Talbot, L Moro, R Talamini and DJ Baylink
Department of Mineral Metabolism, Jerry L. Pettis Veterans Administration Hospital, Loma Linda, California 92357, USA.

We have previously shown that galactosyl hydroxylysine (GHYL), pyridinoline (PYD), and deoxypyridinoline (DPD) have a better accuracy and discriminate power than hydroxyproline in distinguishing postmenopausal osteoporotic women from premenopausal controls. In this study, we evaluated the clinical performances of GHYL, PYD, and DPD, alone or in combination, in distinguishing postmenopausal osteoporotic women (OPBD, n = 26) from age-matched controls (CBD, n = 19). The diagnosis of osteoporosis was based upon the bone density (BD) of the lumbar spine measured by quantitative computed tomography (CBD: BD > 108 mg/cm3; OPBD: BD < 70 mg/cm3). Urinary excretion of GHYL, PYD, and DPD were measured by HPLC, and all data were expressed as the molar ratio with the creatinine excretion (GHYL/CR, PYD/CR, and DPD/CR). The clinical performances were tested by: Z score analysis (Z), Receiver Operated Characteristic curve analysis (%Acc) and logistic-regression analysis of the posterior probabilities for prediction from a logistic model (LOGIST). GHYL/CR, PYD/CR, and DPD/CR were significantly increased in OPBD compared with CBD. The clinical performances were similar for the three assays, with slightly better performances for GHYL/CR (GHYL/CR: Z = 3.14, %Acc = 70 +/- 8, LOGIST P = 0.01; PYD/CR: Z = 2.19, %Acc = 67 +/- 8, LOGIST P = 0.051; DPD/CR: Z = 2.13, %Acc = 65 +/- 8, LOGIST P = 0.06). None of the possible combinations of the three assays yielded better clinical performances than GHYL/CR alone. In conclusion, this study further confirms the validity of GHYL, PYD, and DPD as markers of bone resorption.

This article has been cited by other articles:

				C. Libanati, D. J. Baylink, E. Lois-Wenzel, N. Srinivasan, and S. Mohan Studies on the Potential Mediators of Skeletal Changes Occurring during Puberty in Girls J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2807 - 2814. [Abstract] [Full Text]

				N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]

				T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation Clin. Chem., October 1, 1998; 44(10): 2126 - 2132. [Abstract] [Full Text] [PDF]

				P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039. [Abstract] [Full Text] [PDF]